June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
New in vitro model of photoreceptor degeneration based on the 661W cell line
Author Affiliations & Notes
  • Valeria Marigo
    Life Sciences, Universita degli Studi di Modena e Reggio Emilia, Modena, Emilia-Romagna, Italy
  • Li Huang
    Life Sciences, Universita degli Studi di Modena e Reggio Emilia, Modena, Emilia-Romagna, Italy
  • Meltem Kutluer
    Life Sciences, Universita degli Studi di Modena e Reggio Emilia, Modena, Emilia-Romagna, Italy
  • Elisa Adani
    Life Sciences, Universita degli Studi di Modena e Reggio Emilia, Modena, Emilia-Romagna, Italy
  • Footnotes
    Commercial Relationships   Valeria Marigo, None; Li Huang, None; Meltem Kutluer, None; Elisa Adani, None
  • Footnotes
    Support  European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 765441, Funding from Italian Telethon Foundation GGP19113
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 3068. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Valeria Marigo, Li Huang, Meltem Kutluer, Elisa Adani; New in vitro model of photoreceptor degeneration based on the 661W cell line. Invest. Ophthalmol. Vis. Sci. 2021;62(8):3068.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinitis Pigmentosa (RP) is an inherited degenerative disease characterized by photoreceptor cell death. Several studies, mostly in Pde6b mutant retinas, identified the mechanisms of rod photoreceptor cell death involving excess of intracellular calcium and cGMP, activation of calpain and PKG and nuclear translocation of AIF. One of the limits that hamper the development of novel therapeutic strategies resides on the lack of a reliable in vitro system for high-throughput drug screenings. The purpose of this study was to generate a genetically modified cell line, derived from 661W photoreceptor progenitor cells, able to model the disease in vitro.

Methods : 661W cells were genetically modified to stably express the neural retina leucine zipper (NRL) rod specific transcription factor. qPCR and immunofluorescence were used to select a clone, highly expressing rod specific genes. Cell differentiation was achieved with a culture medium containing retinoic acid (RA), basic fibroblast growth factor (bFGF), taurine and sodium butyrate. A stress protocol for mimicking photoreceptor degeneration was based on the the PDE6 inhibitor zaprinast.

Results : 661W cells were infected with a retrovirus expressing the NRL transcription factor. Out of 14 cell clones, one was selected based on expression of Nrl and Cnga1 genes. qPCR analyzed rod-specific gene expression, such as Rho, Pde6b, Cngb1, Gnat, Guca, Crx, and showed significant higher levels in this clone compared to the 661W cell line. Cone-specific genes, otherwise, did not change level of expression. We developed a differentiation protocol based on FBS withdrawal and exposure to bFGF, RA, Taurine and sodium butyrate. After differentiation, based on qPCR and immunofluorescence, cells showed an elongated shape and augmented expression of rod specific genes, when compared to not differentiated cells. To mimic the degeneration process caused by increased cGMP, we exposed the cells to zaprinast, an inhibitor of PDE6, and found an increased cell death accompanied by increased intracellular calcium and calpain activation. The effects of known, previously published, neuroprotective agents were tested in the new in vitro model.

Conclusions : The new in vitro model for rod photoreceptor degeneration will be instrumental for high-throughput screenings and testing of new compounds that can act as novel therapeutic approaches for this blinding disease.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×